Skip to content

Peptides, hormones and pipeline drugs

CJC-1295

CJC-1295 is an unapproved, lab-made peptide that mimics growth hormone-releasing hormone and is marketed online for fat loss and muscle gain.

Clinician review pending Updated Peptides, hormones and pipeline drugs
DefinitionCJC-1295 is an unapproved, lab-made peptide that mimics growth hormone-releasing hormone and is marketed online for fat loss and muscle gain.

What it means

CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH), designed to last longer in the body and raise growth hormone levels. It was studied in small early human trials in the 2000s but never approved as a medicine.

The FDA lists CJC-1295 among bulk substances nominated for compounding that may raise significant safety concerns. The agency noted possible immune reactions, reports of serious adverse events including increased heart rate and a whole-body blood vessel reaction, and limited clinical data.

There is no good evidence that CJC-1295 causes meaningful weight loss in people. It is often sold online labeled "for research use only" and in combination with ipamorelin, without any FDA review of what is in the vial.

Tesamorelin is the related approved GHRH medicine, and it has a narrow label that excludes weight loss.

Why it matters

CJC-1295 is sold with fat-loss claims that no approved label or solid trial supports.

Related terms

IpamorelinTesamorelinResearch peptides ("not for human use")PeptideWhat are peptides for weight loss

Sources

  1. FDA: Bulk drug substances that may present significant safety risks

Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error